Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder (Q39347371)

11 September 2017

Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder (English)

1 reference

11 September 2017

0 references

0 references

1 reference

Christopher J McDougle

7

object named as

Christopher J McDougle

1 reference

11 September 2017

Craig A Erickson

1

1 reference

11 September 2017

Logan K Wink

2

1 reference

11 September 2017

Maureen C Early

3

1 reference

11 September 2017

Elizabeth Stiegelmeyer

4

1 reference

11 September 2017

Lauren Mathieu-Frasier

5

1 reference

11 September 2017

Vanessa Patrick

6

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 April 2014

1 reference

Journal of Autism and Developmental Disorders

11 September 2017

1 reference

11 September 2017

44

1 reference

11 September 2017

4

1 reference

11 September 2017

981-987

1 reference

https://scigraph.springernature.com/pub.10.1007/s10803-013-1943-3

11 September 2017

0 references

cites work

Therapeutic implications of the mGluR theory of fragile X mental retardation

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

The mGluR theory of fragile X mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Decreased expression of the GABAA receptor in fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

The GABAA receptor: a novel target for treatment of fragile X?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Brief report: acamprosate in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Acamprosate: recent findings and future research directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Developing drugs for core social and communication impairment in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Effects of Acamprosate on Neuronal Receptors and Ion Channels Expressed inXenopusOocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Neocortical excitation/inhibition balance in information processing and social dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-013-1943-3

Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome

21 January 2018

1 reference

12 December 2020

Neurochemistry in the pathophysiology of autism.

1 reference

12 December 2020

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

1 reference

12 December 2020

Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice

1 reference

12 December 2020

10.1007/S10803-013-1943-3

Identifiers

DOI

1 reference

11 September 2017

1 reference